Markets:

Overview

News

Currencies

International

Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

82.12 +0.55 (+0.67%)

Streaming Delayed Price Updated: 2:41 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 03, 2024

Via Benzinga

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program ↗

December 02, 2024

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties.

Via Benzinga

XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗

December 02, 2024

Via Benzinga

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone ↗

December 02, 2024

The deal focuses on the company's treatment for Huntington's disease.

Via Investor's Business Daily

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs ↗

November 27, 2024

PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntington's and PKU programs.

Via Benzinga

Earnings Preview For PTC Therapeutics ↗

November 06, 2024

Via Benzinga

Recap: PTC Therapeutics Q4 Earnings ↗

February 29, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain ↗

November 14, 2024

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment.

Via Benzinga

3 Top Stocks That Could Still Rocket Higher in 2024 ↗

October 04, 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Via The Motley Fool

PTC Therapeutics Stock Earns RS Rating Upgrade To 83 ↗

August 19, 2024

The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.

Via Investor's Business Daily

PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 10, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Earnings Preview: PTC Therapeutics ↗

February 28, 2024

Via Benzinga

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 03, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 28, 2024

Via Benzinga

PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again ↗

June 28, 2024

The company plans to ask for another re-examination for its drug in Europe.

Via Investor's Business Daily

Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday ↗

June 21, 2024

Via Benzinga

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder ↗

June 20, 2024

PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program.

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗

June 04, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

Via InvestorPlace

Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

May 20, 2024

Via Benzinga

European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance ↗

May 20, 2024

PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available...

Via Benzinga

Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday ↗

May 20, 2024

Via Benzinga

PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day' ↗

May 20, 2024

The EC is asking its committee to reexamine its decision on Translarna.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 20, 2024

Via Benzinga

PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 ↗

May 01, 2024

PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.

Via Investor's Business Daily

PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

April 25, 2024

PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? ↗

February 11, 2024

Bad news for one player does not always equal good news for another.

Via The Motley Fool

PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug ↗

January 26, 2024

European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.